Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study
Abstract Background Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role in the development of vascular events. Measurement of the peripheral v...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | Cardio-Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40959-023-00164-3 |
| _version_ | 1797863428585422848 |
|---|---|
| author | Tomohiro Kaneko Sakiko Miyazaki Azusa Kurita Ryoko Morimoto Shun Tsuchiya Naoki Watanabe Tomoiku Takaku Norio Komatsu Tohru Minamino |
| author_facet | Tomohiro Kaneko Sakiko Miyazaki Azusa Kurita Ryoko Morimoto Shun Tsuchiya Naoki Watanabe Tomoiku Takaku Norio Komatsu Tohru Minamino |
| author_sort | Tomohiro Kaneko |
| collection | DOAJ |
| description | Abstract Background Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role in the development of vascular events. Measurement of the peripheral vasodilator response by peripheral arterial tonometry (PAT) has reportedly been useful in the non-invasive assessment of endothelial dysfunction. To date, no studies have assessed endothelial function using PAT in patients with CML receiving TKIs. Method We measured the reactive hyperemia index (RHI) using PAT in young patients with CML (men aged ≤ 55 years and women aged ≤ 65 years) receiving TKIs. Results Thirty patients with CML were examined (mean age, 43.5 ± 9.8 years; men, 57%). The median RHI was 1.81. Among these patients, 16.7% and 83.3% were taking imatinib and second- or third-generation TKIs, respectively. There were no differences in the baseline characteristics between the low RHI (< 1.67, n = 10), borderline RHI (≥ 1.67 and < 2.10, n = 14), and normal RHI (≥ 2.10, n = 6) groups. Serum uric acid (UA) levels and the RHI were significantly negatively correlated (r = -0.40, p = 0.029). Conclusion One-third of young patients with CML receiving TKI therapy were classified as having a low RHI. The RHI was negatively correlated with serum UA level. Larger prospective studies are necessary to examine whether the RHI predicts cardiovascular events in such patients. |
| first_indexed | 2024-04-09T22:35:25Z |
| format | Article |
| id | doaj.art-d192425321a6433db062caf610009180 |
| institution | Directory Open Access Journal |
| issn | 2057-3804 |
| language | English |
| last_indexed | 2024-04-09T22:35:25Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardio-Oncology |
| spelling | doaj.art-d192425321a6433db062caf6100091802023-03-22T12:31:30ZengBMCCardio-Oncology2057-38042023-02-01911810.1186/s40959-023-00164-3Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot studyTomohiro Kaneko0Sakiko Miyazaki1Azusa Kurita2Ryoko Morimoto3Shun Tsuchiya4Naoki Watanabe5Tomoiku Takaku6Norio Komatsu7Tohru Minamino8Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of MedicineDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of MedicineDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of MedicineDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of MedicineDepartment of Hematology, Juntendo University Graduate School of MedicineDepartment of Hematology, Juntendo University Graduate School of MedicineDepartment of Hematology, Juntendo University Graduate School of MedicineDepartment of Hematology, Juntendo University Graduate School of MedicineDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of MedicineAbstract Background Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role in the development of vascular events. Measurement of the peripheral vasodilator response by peripheral arterial tonometry (PAT) has reportedly been useful in the non-invasive assessment of endothelial dysfunction. To date, no studies have assessed endothelial function using PAT in patients with CML receiving TKIs. Method We measured the reactive hyperemia index (RHI) using PAT in young patients with CML (men aged ≤ 55 years and women aged ≤ 65 years) receiving TKIs. Results Thirty patients with CML were examined (mean age, 43.5 ± 9.8 years; men, 57%). The median RHI was 1.81. Among these patients, 16.7% and 83.3% were taking imatinib and second- or third-generation TKIs, respectively. There were no differences in the baseline characteristics between the low RHI (< 1.67, n = 10), borderline RHI (≥ 1.67 and < 2.10, n = 14), and normal RHI (≥ 2.10, n = 6) groups. Serum uric acid (UA) levels and the RHI were significantly negatively correlated (r = -0.40, p = 0.029). Conclusion One-third of young patients with CML receiving TKI therapy were classified as having a low RHI. The RHI was negatively correlated with serum UA level. Larger prospective studies are necessary to examine whether the RHI predicts cardiovascular events in such patients.https://doi.org/10.1186/s40959-023-00164-3Tyrosine kinase inhibitorsChronic myeloid leukemiaEndothelial dysfunctionUric acid |
| spellingShingle | Tomohiro Kaneko Sakiko Miyazaki Azusa Kurita Ryoko Morimoto Shun Tsuchiya Naoki Watanabe Tomoiku Takaku Norio Komatsu Tohru Minamino Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study Cardio-Oncology Tyrosine kinase inhibitors Chronic myeloid leukemia Endothelial dysfunction Uric acid |
| title | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
| title_full | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
| title_fullStr | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
| title_full_unstemmed | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
| title_short | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
| title_sort | endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy a pilot study |
| topic | Tyrosine kinase inhibitors Chronic myeloid leukemia Endothelial dysfunction Uric acid |
| url | https://doi.org/10.1186/s40959-023-00164-3 |
| work_keys_str_mv | AT tomohirokaneko endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT sakikomiyazaki endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT azusakurita endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT ryokomorimoto endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT shuntsuchiya endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT naokiwatanabe endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT tomoikutakaku endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT noriokomatsu endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT tohruminamino endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy |